Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.

NCT07748689 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

228

Enrollment

OTHER

Sponsor class

Conditions

Relapsed / Refractory Multiple Myeloma

Interventions

DRUG: Belantamab Mafodotin
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Polish Myeloma Consortium

Collaborators

[object Object]
[object Object]